Peapod Bio appoints Michael Scholle, MS, MBA to Board of Directors

Appointment brings over fifteen years as a CRO executive

Peapod Bio, Inc, an industry leading contract research organization for small molecule assay development and high-throughput screening solutions, announced the appointment of Michael Scholle, MS, MBA, to its board of directors, effective immediately.

Scholle brings over twenty-five years of experience in assay development and high-throughput screening solutions for small molecule and peptide drug discovery, along with molecular biology, protein engineering, and experience integrating automated solutions. He is the Chief Executive Officer and Co-Founder of Tango Biosciences, Inc., a CRO that offers affinity reagent and peptide discovery solutions using phage display.

“Mr. Scholle’s track record of building successful biotech companies is stellar and his expertise in developing efficient and robust commercial operations will support our growth strategy,” states Zachary Gurard-Levin, CEO for Peapod Bio. “His expertise in merging science and business will be an invaluable resource to Peapod Bio.”

“I am honored to be on the Board of Directors and support Peapod Bio into its next phase of growth and expansion of its industry leading solutions in small molecule drug discovery.” adds Scholle.